Immunological off-target effects of standard treatments in gastrointestinal cancers

Por Duffy, A. G., Greten, T. F.
Publicado em 2014

The case for immune-based approaches in biliary tract carcinoma

Por Duffy, A.G., Makarova-Rusher, O.V., Greten, T.F.
Publicado no Hepatology (2016)

Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750—an antisense oligonucleotide against eIF4E—in combination with irinoteca...

Por Duffy, A.G., Makarova-Rusher, O.V., Ulahannan, S.V., Rahma, O.E., Fioravanti, S., Walker, M., Abdullah, S., Raffeld, M., Anderson, V., Abi-Jaoudeh, N., Levy, E., Wood, B.J., Lee, S., Tomita, Y., Trepel, J.B., Steinberg, S.M., Revenko, A.S., MacLeod, A.R., Peer, C.J., Figg, W.D., Greten, T.F.
Publicado no Int J Cancer (2016)